[8-K] Moleculin Biotech, Inc. Reports Material Event
Moleculin Biotech, Inc. filed a Current Report on Form 8-K disclosing that on September 8, 2025 the company posted and is using an Investor Presentation dated September 2025 as its corporate presentation and furnished that presentation as Exhibit 99.1. The filing states the furnished presentation is not being "filed" under the Exchange Act and will not be incorporated by reference into future filings unless expressly identified. The report identifies the registrant, principal executive office address in Houston, Texas, trading symbol MBRX on NASDAQ, and includes the Exhibit list and Inline XBRL cover page reference.
Moleculin Biotech, Inc. ha presentato un Current Report sul modulo 8-K, comunicando che l'8 settembre 2025 la societ脿 ha pubblicato e utilizza una Presentazione per Investitori datata settembre 2025 come presentazione aziendale e ha fornito tale presentazione come Allegato 99.1. Nel documento si precisa che la presentazione fornita non 猫 "depositata" ai sensi dell'Exchange Act e non sar脿 incorporata per riferimento in future comunicazioni, salvo esplicita indicazione. Il rapporto indica il registrante, l'indirizzo della sede principale a Houston, Texas, il simbolo di negoziazione MBRX su NASDAQ e include l'elenco degli allegati e il riferimento alla cover page Inline XBRL.
Moleculin Biotech, Inc. present贸 un Current Report en el Formulario 8-K informando que el 8 de septiembre de 2025 la compa帽铆a public贸 y est谩 usando una Presentaci贸n para Inversores con fecha septiembre de 2025 como su presentaci贸n corporativa y aport贸 dicha presentaci贸n como el Anexo 99.1. El documento aclara que la presentaci贸n aportada no se est谩 "presentando" conforme al Exchange Act y no se incorporar谩 por referencia en futuros documentos salvo que se indique expresamente. El informe identifica al registrante, la direcci贸n de la oficina principal en Houston, Texas, el s铆mbolo de cotizaci贸n MBRX en NASDAQ e incluye la lista de anexos y la referencia a la portada Inline XBRL.
Moleculin Biotech, Inc.電� 8-K 氤搓碃靹�(Current Report on Form 8-K)毳� 鞝滌稖頃橃棳 2025雲� 9鞗� 8鞚� 須岇偓臧� 2025雲� 9鞗旍瀽 韴瀽鞛� 頂勲爤鞝犿厡鞚挫厴鞚� 瓴岇嫓頃橃棳 須岇偓 瓿奠嫕 頂勲爤鞝犿厡鞚挫厴鞙茧 靷毄頃橁碃 頃措嫻 鞛愲毳� 歃濍箼靹滊 Exhibit 99.1搿� 鞝滉车頄堧嫟瓿� 瓿奠嫓頄堨姷雼堧嫟. 鞝滌稖靹滌棎電� 鞝滉车霅� 頂勲爤鞝犿厡鞚挫厴鞚� Exchange Act鞐� 霐半澕 "鞝滌稖"霅橂姅 瓴冹澊 鞎勲媹氅� 氇呾嫓鞝侅溂搿� 歆�鞝曤悩歆� 鞎婋姅 頃� 頄ロ泟 鞝滌稖靹滊鞐� 彀胳“搿� 韱淀暕霅橃 鞎婌潉 瓴冹澊霛缄碃 氇呾嫓霅橃柎 鞛堨姷雼堧嫟. 氤搓碃靹滌棎電� 霌彪鞚�, 韰嶌偓鞀� 頊挫姢韯挫棎 鞛堧姅 雽�響� 靷靻� 欤检唽, NASDAQ 靸侅灔 鞁臣 MBRX, 攴鸽Μ瓿� 鞝勳嫓氍� 氇╇ 氚� Inline XBRL 旎る矂 韼橃澊歆� 彀胳“臧� 韽暔霅橃柎 鞛堨姷雼堧嫟.
Moleculin Biotech, Inc. a d茅pos茅 un Current Report sur le formulaire 8-K indiquant que, le 8 septembre 2025, la soci茅t茅 a publi茅 et utilise une Pr茅sentation aux investisseurs dat茅e de septembre 2025 comme pr茅sentation d'entreprise et a fourni cette pr茅sentation en tant qu'Exhibit 99.1. Le d茅p么t pr茅cise que la pr茅sentation fournie n'est pas 芦 d茅pos茅e 禄 en vertu de l'Exchange Act et ne sera pas incorpor茅e par r茅f茅rence dans des d茅p么ts futurs sauf indication expresse. Le rapport identifie l'enregistrant, l'adresse du bureau principal 脿 Houston, Texas, le symbole de cotation MBRX sur le NASDAQ, et inclut la liste des annexes ainsi que la r茅f茅rence 脿 la page de couverture Inline XBRL.
Moleculin Biotech, Inc. hat einen Current Report auf Formular 8-K eingereicht und mitgeteilt, dass das Unternehmen am 8. September 2025 eine Investor Presentation vom September 2025 ver枚ffentlicht und als Unternehmenspr盲sentation verwendet hat und diese Pr盲sentation als Anlage 99.1 beigef眉gt wurde. In der Einreichung wird klargestellt, dass die beigef眉gte Pr盲sentation nicht im Sinne des Exchange Act "eingereicht" wird und nicht durch Verweis in k眉nftige Einreichungen aufgenommen wird, sofern nicht ausdr眉cklich angegeben. Der Bericht nennt den Registranten, die Anschrift der Hauptgesch盲ftsstelle in Houston, Texas, das Handelssymbol MBRX an der NASDAQ und enth盲lt die Liste der Anlagen sowie den Verweis auf die Inline-XBRL-Titelseite.
- None.
- None.
Insights
TL;DR: Routine Regulation FD disclosure; an investor deck was furnished, not filed, which is a standard corporate communications step.
The company furnished an investor presentation as Exhibit 99.1 under Item 7.01, indicating it is distributing updated corporate materials on September 8, 2025. This disclosure follows Regulation FD practice by making the presentation publicly available and clarifies it is being furnished rather than filed, limiting automatic incorporation into SEC filings. For investors, this is a transparency/communications action rather than a financial event; no earnings, material transactions, or financial statements are included in this 8-K.
TL;DR: Filing is procedural and compliant; furnishing an investor presentation is standard and signals outreach but has no standalone material financial impact.
The Form 8-K properly discloses the furnishing of corporate presentation materials and includes the required exhibit reference (99.1). The statement that the exhibit is furnished and not filed aligns with common disclosure practice to avoid automatic incorporation by reference. This is a governance-level communications event rather than a material corporate action, and the filing contains the expected cover and exhibit references without additional substantive corporate changes.
Moleculin Biotech, Inc. ha presentato un Current Report sul modulo 8-K, comunicando che l'8 settembre 2025 la societ脿 ha pubblicato e utilizza una Presentazione per Investitori datata settembre 2025 come presentazione aziendale e ha fornito tale presentazione come Allegato 99.1. Nel documento si precisa che la presentazione fornita non 猫 "depositata" ai sensi dell'Exchange Act e non sar脿 incorporata per riferimento in future comunicazioni, salvo esplicita indicazione. Il rapporto indica il registrante, l'indirizzo della sede principale a Houston, Texas, il simbolo di negoziazione MBRX su NASDAQ e include l'elenco degli allegati e il riferimento alla cover page Inline XBRL.
Moleculin Biotech, Inc. present贸 un Current Report en el Formulario 8-K informando que el 8 de septiembre de 2025 la compa帽铆a public贸 y est谩 usando una Presentaci贸n para Inversores con fecha septiembre de 2025 como su presentaci贸n corporativa y aport贸 dicha presentaci贸n como el Anexo 99.1. El documento aclara que la presentaci贸n aportada no se est谩 "presentando" conforme al Exchange Act y no se incorporar谩 por referencia en futuros documentos salvo que se indique expresamente. El informe identifica al registrante, la direcci贸n de la oficina principal en Houston, Texas, el s铆mbolo de cotizaci贸n MBRX en NASDAQ e incluye la lista de anexos y la referencia a la portada Inline XBRL.
Moleculin Biotech, Inc.電� 8-K 氤搓碃靹�(Current Report on Form 8-K)毳� 鞝滌稖頃橃棳 2025雲� 9鞗� 8鞚� 須岇偓臧� 2025雲� 9鞗旍瀽 韴瀽鞛� 頂勲爤鞝犿厡鞚挫厴鞚� 瓴岇嫓頃橃棳 須岇偓 瓿奠嫕 頂勲爤鞝犿厡鞚挫厴鞙茧 靷毄頃橁碃 頃措嫻 鞛愲毳� 歃濍箼靹滊 Exhibit 99.1搿� 鞝滉车頄堧嫟瓿� 瓿奠嫓頄堨姷雼堧嫟. 鞝滌稖靹滌棎電� 鞝滉车霅� 頂勲爤鞝犿厡鞚挫厴鞚� Exchange Act鞐� 霐半澕 "鞝滌稖"霅橂姅 瓴冹澊 鞎勲媹氅� 氇呾嫓鞝侅溂搿� 歆�鞝曤悩歆� 鞎婋姅 頃� 頄ロ泟 鞝滌稖靹滊鞐� 彀胳“搿� 韱淀暕霅橃 鞎婌潉 瓴冹澊霛缄碃 氇呾嫓霅橃柎 鞛堨姷雼堧嫟. 氤搓碃靹滌棎電� 霌彪鞚�, 韰嶌偓鞀� 頊挫姢韯挫棎 鞛堧姅 雽�響� 靷靻� 欤检唽, NASDAQ 靸侅灔 鞁臣 MBRX, 攴鸽Μ瓿� 鞝勳嫓氍� 氇╇ 氚� Inline XBRL 旎る矂 韼橃澊歆� 彀胳“臧� 韽暔霅橃柎 鞛堨姷雼堧嫟.
Moleculin Biotech, Inc. a d茅pos茅 un Current Report sur le formulaire 8-K indiquant que, le 8 septembre 2025, la soci茅t茅 a publi茅 et utilise une Pr茅sentation aux investisseurs dat茅e de septembre 2025 comme pr茅sentation d'entreprise et a fourni cette pr茅sentation en tant qu'Exhibit 99.1. Le d茅p么t pr茅cise que la pr茅sentation fournie n'est pas 芦 d茅pos茅e 禄 en vertu de l'Exchange Act et ne sera pas incorpor茅e par r茅f茅rence dans des d茅p么ts futurs sauf indication expresse. Le rapport identifie l'enregistrant, l'adresse du bureau principal 脿 Houston, Texas, le symbole de cotation MBRX sur le NASDAQ, et inclut la liste des annexes ainsi que la r茅f茅rence 脿 la page de couverture Inline XBRL.
Moleculin Biotech, Inc. hat einen Current Report auf Formular 8-K eingereicht und mitgeteilt, dass das Unternehmen am 8. September 2025 eine Investor Presentation vom September 2025 ver枚ffentlicht und als Unternehmenspr盲sentation verwendet hat und diese Pr盲sentation als Anlage 99.1 beigef眉gt wurde. In der Einreichung wird klargestellt, dass die beigef眉gte Pr盲sentation nicht im Sinne des Exchange Act "eingereicht" wird und nicht durch Verweis in k眉nftige Einreichungen aufgenommen wird, sofern nicht ausdr眉cklich angegeben. Der Bericht nennt den Registranten, die Anschrift der Hauptgesch盲ftsstelle in Houston, Texas, das Handelssymbol MBRX an der NASDAQ und enth盲lt die Liste der Anlagen sowie den Verweis auf die Inline-XBRL-Titelseite.
|
|
|
|
|
(State or Other Jurisdiction of
Incorporation or Organization)
|
(Commission File No.)
|
(I.R.S. Employer Identification No.)
|
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-14(c))
|
|
Title of each class
|
Trading Symbol (s)
|
Name of each exchange on which registered
|
|
|
|
The
|
|
Item 7.01
|
Regulation FD Disclosure
|
|
Item 9.01
|
Financial Statements and Exhibits.
|
|
(d)
|
Exhibits.
|
|
Exhibit No.
|
Description
|
|
99.1
|
InvestorPresentation dated September 2025
|
|
104
|
Cover page Interactive Data File (formatted as Inline XBRL document)
|
|
MOLECULIN BIOTECH, INC.
|
|||
|
Date:
|
September 8, 2025
|
||
|
By:
|
/s/ Jonathan P. Foster
|
||
|
Jonathan P. Foster
|
|||
Source:
